Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal Pain and Corneal Epitheliopathy

Next Previous
Trial Profile

Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal Pain and Corneal Epitheliopathy

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Chlorine dioxide (Primary) ; Povidone iodine
  • Indications Endophthalmitis; Ocular pain
  • Focus Registrational; Therapeutic Use
  • Acronyms COMFORT
  • Sponsors iRenix Medical; Tarsus Pharmaceuticals

Most Recent Events

  • 09 Jul 2026 According to Tarsus Pharmaceuticals media release, iRenix Medical has been acquired and merged into Tarsus Pharmaceuticals.
  • 08 Jul 2026 According to a Tarsus Pharmaceuticals media release, based on phase 2b/3 trial data and in alignment with feedback from the U.S. Food and Drug Administration, company plans to initiate a Phase 3 study designed to evaluate the tolerability and safety of IRX-101 compared to povidone-iodine. The study is expected to begin enrolling in the first half of 2027 with results anticipated in 2028.
  • 03 Apr 2026 Planned End Date changed from 31 Dec 2027 to 31 Jan 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top